Aerpio Pharmaceuticals with ticker code (ARPO) have now 2 analysts in total covering the stock. The consensus rating is ‘Buy’. The target price ranges between 2 and 1.5 with a mean TP of 1.75. Now with the previous closing price of 0.98 this would imply there is a potential upside of 78.6%. The 50 day MA is 1.47 and the 200 day moving average is 1.4. The company has a market cap of $49m. Company Website: http://www.aerpio.com
Aerpio Pharmaceuticals, a biopharmaceutical company, focuses on developing and commercializing compounds for the treatment of ocular diseases and diabetic complications. The company’s lead product candidate is razuprotafib, a small molecule activator of the Tie2 pathway, which completed the Phase IIb clinical trial for the treatment of diabetic retinopathy. It also develops ARP-1536, a humanized monoclonal antibody that is in preclinical development stage for the treatment of diabetic vascular complications; GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, which is in a Phase 1b clinical trial for the treatment of inflammatory bowel disease; and bispecific antibody for the treatment for wet age-related macular degeneration and DME through intravitreal injection. Aerpio Pharmaceuticals has a collaboration with Quantum Leap Healthcare Collaborative for the evaluation of razuprotafib in the treatment of acute respiratory distress syndrome in adult patients with moderate to severe COVID-19. The company is headquartered in Cincinnati, Ohio.